Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083334 | 0.91 | MAOB (0.57) | ALDH1A1MAOBNR4A2ADAM17CYP4F2 | |
| SCHEMBL7802749 | 0.90 | ADAM17 (0.54) | ALDH1A1ALOX5MAOBNR4A2ADAM17 | |
| SCHEMBL7810973 | 0.88 | AKR1C1 (0.55) | ALDH1A1ALOX5MAOBNR4A2ADAM17 | |
| SCHEMBL23163726 | 0.88 | ADAM17 (0.57) | ALDH1A1ALOX5MAOBADAM17 | |
| SCHEMBL7810873 | 0.86 | ALOX5 (0.67) | ALDH1A1ALOX5ADAM17 | |
| SCHEMBL23163539 | 0.86 | MMP1 (0.53) | ALDH1A1ALOX5MAOBNR4A2KMT2A | |
| SCHEMBL11069452 | 0.85 | ALOX5 (0.53) | ALDH1A1ALOX5MAOBNR4A2ADAM17 | |
| SCHEMBL7802551 | 0.84 | ALOX5 (0.56) | ALOX5 | |
| SCHEMBL9217663 | 0.83 | ALOX5 (0.61) | ALDH1A1ALOX5 | |
| SCHEMBL7475156 | 0.82 | ALOX5 (0.47) | ALDH1A1ALOX5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-12-01 | — | — | US | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| EP-0787127-B1 | 5-LIPOXYGENASE INHIBITORS | PFIZER (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6063928-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, CARDIOTONIC AGENTS | PFIZER INC (US) | 2000-05-16 | — | — | US | disclosed |
| US-5883106-A | 5-lipoxygenase inhibitors | PFIZER INC. (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0787127-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996011911-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | ALDH1A1 687/4885ALOX5 33/4885MAOB 2612/4885 |
| US-20220378772-A1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER2 | ALDH1A1 950/4885ALOX5 22/4885MAOB 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.